

No Circulating Cytomegalovirus in Five Patients with Glioblastoma Multiforme

STEVEN LEHRER¹, VINCENT LABOMBARDI², SHERYL GREEN¹, MELISSA S. PESSIN-MINSLEY², ISABELLE M. GERMANO³ and KENNETH E. ROSENZWEIG¹

Departments of ¹Radiation Oncology, ²Pathology and ³Neurosurgery, Mount Sinai School of Medicine, New York, NY, U.S.A.

Abstract. *Background:* Glioblastoma multiforme is the most common and most aggressive type of primary brain tumor, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumors. Recently, evidence for a viral cause has been postulated, possibly SV40 or more likely cytomegalovirus (CMV). One report indicated that 80% of patients with newly diagnosed glioblastoma multiforme have detectable cytomegalovirus DNA in their peripheral blood, while sero-positive normal donors and other surgical patients did not exhibit detectable virus. *Patients and Methods:* In the current study, we examined peripheral blood of 5 patients with newly diagnosed glioblastoma multiforme. Peripheral blood was collected in anticoagulated tubes from five patients with newly diagnosed glioblastoma multiforme referred for radiation therapy. We used standard methods for detecting CMV by reverse transcriptase–polymerase chain reaction (RT-PCR) and peripheral blood culture. *Results:* None of our patients had circulating CMV. *Conclusion:* There are four subtypes of glioblastoma. We hypothesize that circulating CMV might be limited to some, but not all of these subtypes, and that our failure to detect CMV might be attributed to the fact that none of these patients had the appropriate subtype or subtypes.

Glioblastoma multiforme is the most common and most aggressive type of primary brain tumor, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumors (1). Glioblastoma multiforme is more common in males and appears to be sporadic, without any genetic predisposition. No links have been found between glioblastoma multiforme and smoking, diet, cellular phone

Correspondence to: Dr. Steven Lehrer, Mount Sinai Medical Center, Box 1236, New York 10029, U.S.A. Tel +212 7657132, Fax: +212 2459708, e-mail: stevenlehrer@hotmail.com

Key Words: Brain tumors, cytomegalovirus, glioblastoma, etiology.

use, or electromagnetic fields. The only effective chemotherapy is temodar, an oral alkylating agent, that seems to work as a radiosensitizer (2).

Recently, evidence for a viral cause has been postulated, possibly SV40 (3) or more likely cytomegalovirus (CMV) (4). Cobbs *et al.* reported that a high percentage of malignant gliomas are infected by CMV and multiple CMV gene products are expressed in these tumors (5). Mitchell *et al.* reported that 80% of patients with newly diagnosed glioblastoma multiforme have detectable cytomegalovirus DNA in their peripheral blood, while sero-positive normal donors and other surgical patients did not exhibit detectable virus (4). Mitchell *et al.* suggest an association of CMV with malignant gliomas and propose that subclinical CMV viremia is a previously unrecognized manifestation of glioblastoma multiforme.

In the current study, we examined peripheral blood in five patients with newly diagnosed glioblastoma multiforme.

Patients and Methods

Peripheral blood was collected in anticoagulated tubes from five patients with newly diagnosed glioblastoma multiforme referred for radiation therapy. We used standard methods for detecting CMV by reverse transcriptase–polymerase chain reaction (RT-PCR) (6) and peripheral blood culture (7). Characteristics of the patients are listed in Table I.

Results

None of our five patients had circulating CMV detected either with RT-PCR or blood culture. Mitchell *et al.* reported that 80% of patients with newly diagnosed glioblastoma multiforme have detectable cytomegalovirus DNA in their peripheral blood (4). Therefore, the chance of a single glioblastoma patient not having detectable cytomegalovirus would be 20% or 0.2, and the chance of none of five patients having detectable cytomegalovirus would be $(0.2)^5$ or $p=0.00032$.

Table I. Characteristics of patients in this study. All lesions were primary except for the 22-year-old male, whose tumor arose in the site of an oligodendroglioma treated at age 14.

Age	Gender	Karnofsky score	Presentation	Size (cm)	Position
47	F	100	headaches	4	r. ant temporal
70	M	60	gait disturbance	5	r. temp
22	M	80	seizure	4	l. temp
69	F	90	cognitive disturbance	5	r. parietal
52	M	60	cognitive disturbance, headaches	6	r. frontal

Discussion

CMV is one of 8 human herpesviruses. CMV infects at least half of the population in developed countries, and nearly everyone in developing countries, where poor sanitation and hygiene abet its transmission. Although it generally does not cause problems in healthy adults, CMV is a common cause of birth defects, and it can cause a host of serious problems in immunocompromised people, particularly AIDS patients, who often develop CMV chorioretinitis (8). Moreover, increased CMV antibody levels are associated with impaired cognition, frailty, functional impairment, and increased mortality among community-dwelling older adults (9).

The CMV–glioblastoma association is controversial. It is unclear why CMV, a common virus, would cause glioblastoma in only a small subset of those infected, especially since *in vitro* studies have failed to show that CMV transforms normal cells into cancerous cells. Yet some preliminary results indicate Valcyte (Roche), an antiviral drug, may improve prognosis in glioblastoma patients, despite the questionable CMV association (8).

Our own inability to find circulating CMV in five glioblastoma multiforme patients might be explained by the recent discovery of four genomic glioblastoma multiforme subtypes (10, 11). We hypothesize that circulating CMV might be limited to some, not all, of these subtypes, and that our failure to detect CMV might be attributed to the fact that none of these five patients had the appropriate subtype or subtypes. A larger study would be worthwhile.

References

- Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. *Acta Neuropathol 109(1)*: 93-108, 2005.
- Chamberlain MC, Glantz MJ, Chalmers L, Van HA and Sloan AE: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. *J Neurooncol 82(1)*: 81-83, 2007.
- Tognon M, Casalone R, Martini F, De MM, Granata P, Minelli E, Arcuri C, Collini P and Bocchini V: Large T antigen coding sequences of two DNA tumor viruses, BK and SV40, and nonrandom chromosome changes in two glioblastoma cell lines. *Cancer Genet Cytogenet 90(1)*: 17-23, 1996.
- Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE and Sampson JH: Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. *Neuro Oncol 10(1)*: 10-18, 2008.
- Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG and Britt WJ: Human cytomegalovirus infection and expression in human malignant glioma. *Cancer Res 62(12)*: 3347-3350, 2002.
- Gozlan J, Salord JM, Chouaid C, Duvivier C, Picard O, Meyohas MC and Petit JC: Human cytomegalovirus (HCMV) late-mRNA detection in peripheral blood of AIDS patients: diagnostic value for HCMV disease compared with those of viral culture and HCMV DNA detection. *J Clin Microbiol 31(7)*: 1943, 1993.
- Shibata D, Martin WJ, Appleman MD, Causey DM, Leedom JM and Arnheim N: Detection of cytomegalovirus DNA in peripheral blood of patients infected with human immunodeficiency virus. *J Infect Dis 158(6)*: 1185-1192, 1988.
- Miller G: Brain cancer. A viral link to glioblastoma? *Science 323(5910)*: 30-31, 2009.
- Strandberg TE, Pitkala KH and Tilvis RS: Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. *JAMA 380*: 382, 2009.
- Hayden EC: Genomics boosts brain-cancer work. *Nature 463(7279)*: 278, 2010.
- Kuehn BM: Genomics illuminates a deadly brain cancer. *JAMA 303(10)*: 925-927, 2010.

Received January 5, 2011
 Revised February 22, 2011
 Accepted February 23, 2011